Limb-Girdle Gene Therapy Bididistrogene Xeboparvovec Demonstrates 5-Year Safety in Early-Stage Trial

Over the 5-year period, treatment-related adverse events with the gene therapy were mild or moderate, with most occurring within the first 90 days after infusion.:

Source: Neurology Read More